Form 8-K - Current report:
SEC Accession No. 0001140361-25-032295
Filing Date
2025-08-22
Accepted
2025-08-22 07:05:42
Documents
14
Period of Report
2025-08-18
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K ef20054243_8k.htm   iXBRL 8-K 33906
2 EXHIBIT 99.1 ef20054243_ex99-1.htm EX-99.1 6895
6 image001.jpg GRAPHIC 7145
  Complete submission text file 0001140361-25-032295.txt   185374

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA gyre-20250818.xsd EX-101.SCH 3907
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE gyre-20250818_lab.xml EX-101.LAB 21966
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE gyre-20250818_pre.xml EX-101.PRE 16072
17 EXTRACTED XBRL INSTANCE DOCUMENT ef20054243_8k_htm.xml XML 4205
Mailing Address 12770 HIGH BLUFF DRIVE, SUITE 150 SAN DIEGO CA 92130
Business Address 12770 HIGH BLUFF DRIVE, SUITE 150 SAN DIEGO CA 92130 (619) 949-3681
GYRE THERAPEUTICS, INC. (Filer) CIK: 0001124105 (see all company filings)

EIN.: 562020050 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-51173 | Film No.: 251242183
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)